)
)
)
Hefei TG ImmunoPharma Co., Ltd.
TG ImmunoPharma (TGI) is a clinical-stage biotech company founded in 2020. Founded by Dr. Zhigang Tian — a member of both the Chinese Academy of Engineering and Academia Europaea — the company has established a differentiated portfolio of therapeutic candidates and proprietary technology platforms.
Our key partnership opportunities include:
1) Clinical-stage TCE: B7H6 × CD3 TCE (Phase 1), targeting GI cancers.
2) Preclinical immunocytokines: a portfolio of bispecific and trispecific molecules, including a PD-1/IL-2 α-biased bispecific and a PD-1/IL-2 α-biased/VEGF trispecific.
3) Proprietary technology platform: a novel pH-selective TCE platform designed to minimize cytokine release syndrome (CRS) risk.
4) Autoimmune disease pipeline: Dual- and tri-specific candidates such as BCMA × CD3 and BCMA × CD19 × CD3 for the treatment of autoimmune disorders.
We are actively seeking licensing, co-development, and investment partnerships to advance these promising programs.
Address
HefeiAnhui
China
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)